PERMA-SEAL DIALYSIS ACCESS GRAFT MODEL 2C20

FDA Premarket Approval P980017

This medical device has supplements. The device description/function or indication may have changed. Be sure to look at the supplements to get an up-to-date information on device changes. The labeling included below is the version at time of approval of the original pma or panel track supplement and may not represent the most recent labeling.

Pre-market Approval Supplement Details

Approval for the possis perma-seal(r) dialysis access graft, model 2c20-b. This device is indicated for use as a subcutaneous arteriovenous shunt graft to provide immediate and subsequent chronic blood access for high-efficiency hemodialysis in patients who meet one or more of the following conditons: 1) central venous cannulation is deemed hazardous or is technically unavailable; 2) are being maintained on chronic anticoagulation or antithrombotic therapy; and/or 3) are morbidly obese.

DevicePERMA-SEAL DIALYSIS ACCESS GRAFT MODEL 2C20
ApplicantPOSSIS MEDICAL, INC.
Date Received1997-12-12
Decision Date1998-09-25
PMAP980017
SupplementS
Docket Number98M-0835
Advisory CommitteeCardiovascular
Expedited ReviewYes
Combination Product No
Applicant Address POSSIS MEDICAL, INC. 9055 Evergreen Blvd., N.w. minneapolis, MN 55433-8003

Supplemental Filings

Supplement NumberDateSupplement Type
P980017Original Filing
S001 1998-12-29 Normal 180 Day Track

© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.